These findings suggest that while MMP11+ mCAFs are linked to tumor progression in certain cancers, they are generally associated with poor clinical outcomes across multiple malignancies, highlighting their potential as a universal therapeutic target in cancer treatment. Here, MMP11 is linked to neoplasm.